Semaglutide and effective weight control

Affiliations

¹ Department of Cardiovascular Medicine, Mario Negri Institute of Pharmacological Research IRCCS, 20156 Milan, Italy. Electronic address: roberto.latini@marionegri.it.
² Department of Cardiovascular Medicine, Mario Negri Institute of Pharmacological Research IRCCS, 20156 Milan, Italy.

Comment

Roberto Latini et al. Lancet. 2021.

. 2021 Mar 13;397(10278):942-943.

doi: 10.1016/S0140-6736(21)00377-9. Epub 2021 Mar 2.

¹ Department of Cardiovascular Medicine, Mario Negri Institute of Pharmacological Research IRCCS, 20156 Milan, Italy. Electronic address: roberto.latini@marionegri.it.
² Department of Cardiovascular Medicine, Mario Negri Institute of Pharmacological Research IRCCS, 20156 Milan, Italy.

No abstract available

Comment on

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Davies M, et al. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. Lancet. 2021. PMID: 33667417 Clinical Trial.